Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Me will hold a second auction for its DNA data with an opening bid of $305 million from former CEO Anne Wojcicki. Here's all ...

The judge overseeing the bankruptcy of 23andMe questioned the limits proposed for a second auction that is designed to push ...

Shares of PVH Corp. fell after hours on Wednesday after the Calvin Klein and Tommy Hilfiger parent cut its full-year profit outlook, citing the impact of tariffs on shipments heading into the U.S.

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

Elon Musk has continued to lead as the world's highest-paid CEO, with $23,5 billion in a recent ranking, which showed the top ...

Circle Internet Group, the crypto firm that tried to go public in 2021 but ended up pulling its deal, will finally enter the ...